Table 3.
Baseline (mean±SD) and comparison of change in 6-month (difference [95%CI]) body composition in postmenopausal women treated with placebo, raloxifene, or hormone therapy (HT) who completed the intervention.
| Baseline | Difference in change from Placebo | ||||
|---|---|---|---|---|---|
|
| |||||
| Placebo | Raloxifene | HT | Raloxifene | HT | |
| Anthropometric, n | 28 | 34 | 34 | 34 | 34 |
| Waist, cm | 90.8±13.0 | 92.5±10.4 | 90.9±12.4 | −1.9 [−4.6, 0.8] | 0.3 [−2.4, 3.0] |
| Hip, cm | 111.4±10.1 | 112.9±10.7 | 110.4±9.5 | −1.5 [−4.1, 1.0] | −0.8 [−3.4, 1.7] |
| Thigh, cm | 56.5±5.7 | 56.6±5.8 | 56.1±5.2 | −0.4 [−1.9, 1.1] | −0.0 [−1.5, 1.5] |
| DXA, n | 29 | 34 | 35 | 34 | 35 |
| Weight, kg | 79.5±11.7 | 81.4±13.0 | 79.2±12.9 | −0.7 [−2.4, 1.1] | −0.0 [−1.7, 1.7] |
| FFM, kg | 44.0±5.3 | 45.4±5.9 | 44.9±5.2 | −0.5 [−1.2, 0.2] | −0.1 [−0.8, 0.6] |
| FM, kg | 35.5±8.0 | 36.0±9.2 | 34.3±8.5 | −0.1 [−1.8, 1.6] | 0.0 [−1.7, 1.7] |
| Trunk FM, kg | 17.3±4.2 | 17.8±4.1 | 16.8±4.4 | −0.0 [−1.0, 1.0] | 0.1 [−0.9, 1.1] |
| Leg FM, kg | 13.4±3.3 | 13.2±4.74 | 12.8±3.7 | −0.1 [−0.7, 0.6] | −0.2 [−0.9, 0.4] |
| CT, n | 28 | 27 | 30 | 27 | 30 |
| AFA, cm2 | 473±109 | 487±143 | 479±134 | −13.6 [−41.3, 14.1] | −12.3 [−39.2, 14.7] |
| SFA, cm2 | 355±91 | 361±117 | 344±97 | −10.9 [−30.6, 8.8] | −10.0 [−29.2, 9.2] |
| VFA, cm2 | 118±55 | 126±40 | 135±55 | −2.3 [−13.3, 8.8] | −1.6 [−12.5, 9.2] |
AFA, abdominal fat area; FM, fat mass; FFM, fat-free mass; SFA, subcutaneous fat area, VFA, visceral fat area.